Skip to main content
. 2017 Nov 27;8(67):111144–111160. doi: 10.18632/oncotarget.22676

Figure 7. A simplified model of the mechanisms underlying antitumor effects of cepharanthine hydrochloride (CEH) combined with cisplatin in esophageal squamous cell carcinoma.

Figure 7

(A) CEH result in the reversal of MDR in ESCC through the activation of c-Jun/JNK and P53 signaling pathways. (B) Inhibitors of JNK and p53 can somewhat restore the reversion of MDR mediated by CEH.